Antiplatelet therapy in endovascular treatment for cerebral aneurysms with flow diverter study - APT-ANswer study

Enomoto Yukiko0 个研究点目标入组 434 人开始时间: 2024年1月5日最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1) Patients aged 18 years or older
•2) Patients who have completed flow diverter treatment for cerebral aneurysms
•3) Patients with preoperative mRS 0-2
•4) Patients who have received 2 or more antiplatelet agents (aspirin and clopidogrel or prasugrel) 1 or more days before treatment and continue for at least 1 month after treatment
•5) Patients whose wirtten informed consent has been obtained

•1) Patients with acute ruptured cerebral aneurysm within 2 weeks from onset
•2) Patients with recurrent aneurysms after flow diverter treatment
•3) Patients who did not receive antiplatelet agents at least 1 day before treatment
•4) Patients with severe hepatic impairment (ALT/AST/total bilirubin >5 times normal) or renal impairment (CCr <30 ml/min) at pre-enrollment examination
•5) Patients with a platelet count of less than 50,000/mm3 at the pre-enrollment examination
•6) Patients with comorbidities that require permanent antiplatelet medication, such as coronary artery stenting
•7) Patients who are judged to be inappropriate for the study by the investigators or subinvestigators

发起方

Enomoto Yukiko